Back to search

Article

Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients

2024-09-08

Abstract excerpt

<title>Abstract</title> <p>Background Glioblastoma is the commonest malignant brain tumor and has a very poor prognosis. Reduced expression of the <italic>MGMT</italic> gene (10q26.3), influenced primarily by the methylation of two differentially methylated regions (DMR1 and DMR2), is associated with a good response to temozolomide treatment. However, suitable methods for detecting the methylation of the <italic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
16a8a5f8-0e03-5f4c-b721-8654d2b51d7b
DOI
10.21203/rs.3.rs-4808103/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patientsDOI 10.21203/rs.3.rs-4808103/v1
Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed GlioblastomaSemantic proximity
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesSemantic proximity
RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDSSemantic proximity
Clinical Validation of a Novel Quantitative Assay for the Detection of MGMT Methylation in Glioblastoma PatientsSemantic proximity
Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for brain tumorsSemantic proximity
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity
Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastomaSemantic proximity
Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaSemantic proximity
“Hyper-Hypermethylated Status” of the MGMT Gene Promoter Confers Additional Survival Benefits in IDH-Wild-Type Glioblastoma PatientsSemantic proximity
Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastomaSemantic proximity
MGMT Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in GlioblastomasSemantic proximity
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genesSemantic proximity
Select a neighboring publication to make it the new centre.